gene

CLDN5

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CLDN5: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

391Connections

5Hypotheses

7Analyses

50Outgoing

50Incoming

0Experiments

8Debates

Summary

CLDN5 is a gene implicated in neurodegeneration research. Key relationships include: activates, inhibits, co discussed. Associated with ALS, Als, Brain Arteriovenous Malformations. Connected to 121 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	CLDN5
Full Name	Claudin-5
Chromosome	22q11.21.
Protein Type	Structural Protein
Target Class	Structural Protein
Function	Tight junction protein modulation - no established druggable mechanisms
Mechanism of Action	Tight junction protein modulation - no established druggable mechanisms
Primary Expression	Brain endothelial cells, Tight junctions of blood-brain barrier
Druggability	Undruggable (0.20)
Clinical Stage	Approved
Amino Acids	218 aa
Exons	4
Pathways	Cerebrovascular
UniProt ID	O00511
NCBI Gene ID	9079
Ensembl ID	ENSG00000184113
OMIM	602507
GeneCards	CLDN5
Human Protein Atlas	CLDN5
Associated Diseases	ALS, blood-retinal barrier integrity, Brain Edema, neurodegeneration, stroke
Known Drugs/Compounds	curcumin, resveratrol
Interactions	ABCB1, ABCD1, ABCD2, ABCG2, AMYLOID, AND
SciDEX Target	View Target Profile (5 clinical trials)
SciDEX Hypotheses	Gut-BBB Axis: Tributyrin/Butyrate HDAC Inhibition Plasma Claudin-5 Proteolytic Fragments Distinguish Vascular-Glial Interface Restoration (+2 more)
KG Connections	391 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: CLDN5 — AlphaFold O00511 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

CLDN5 — Claudin-5

gene · 699 words

→

Pathway Diagram

graph TD
    CLDN5["CLDN5"]
    CLDN5 -->|"encodes"| CLAUDIN5["CLAUDIN5"]
    CLDN5 -->|"encodes"| Claudin_5["Claudin-5"]
    CLDN5 -->|"activates"| Stroke["Stroke"]
    CLDN5 -->|"inhibits"| Als["Als"]
    CLDN5 -->|"target for"| Ms["Ms"]
    CLDN5 -->|"inhibits"| ALS["ALS"]
    h_7a8d7379["h-7a8d7379"] -->|"target for"| CLDN5
    H3K27me3["H3K27me3"] -->|"inhibits"| CLDN5
    AUTOPHAGY["AUTOPHAGY"] -->|"regulates"| CLDN5
    OCLN["OCLN"] -->|"activates"| CLDN5
    BECN1["BECN1"] -->|"activates"| CLDN5
    CXCL2["CXCL2"] -->|"inhibits"| CLDN5
    IL6["IL6"] -->|"inhibits"| CLDN5
    ATF4["ATF4"] -->|"target for"| CLDN5
    PPP1R15A["PPP1R15A"] -->|"target for"| CLDN5

Outgoing (253)

Target	Relation	Type	Str
ds-f2c28aed24a7	provides_data_for	dataset	1.00
TIGHT JUNCTION	involved_in	entity	0.95
Blood-Brain Barrier Integrity	regulates	phenotype	0.95
Blood-Retinal Barrier Integrity	promotes	phenotype	0.95
BLOOD-BRAIN BARRIER	involved_in	entity	0.95
Blood-Brain Barrier Integrity	component_of	phenotype	0.95
Blood-Brain Barrier	involved_in	process	0.95
paracellular_BBB_integrity	maintains	process	0.92
BBB	regulates	process	0.90
Blood-Brain Barrier Integrity	involved_in	phenotype	0.90
blood-retinal barrier integrity	associated_with	phenotype	0.90
Brain Arteriovenous Malformations	biomarker_for	disease	0.90
Blood-Brain Barrier Disruption	involved_in	process	0.85
Brain Edema	associated_with	phenotype	0.85
Glioma Progression	downregulates	process	0.85
Tight Junctions	involved_in	process	0.85
MICROGLIA	expressed_in	entity	0.85
Cerebrovascular Disease	therapeutic_target	disease	0.83
CLAUDIN5	encodes	protein	0.80
Stroke	biomarker_for	disease	0.80
Blood-Brain Barrier Disruption	biomarker_for	phenotype	0.80
Brain Arteriovenous Malformations	downregulates	disease	0.80
Cerebral Cortex	expressed_in	brain_region	0.80
blood-brain barrier integrity	mediates	phenotype	0.80
Glioma	downregulates	disease	0.80
claudin_5	encodes	protein	0.80
Glioblastoma	biomarker_for	disease	0.75
OCLN	expressed_in	gene	0.70
ENDOTHELIAL	protects_against	cell_type	0.70
Glioblastoma Multiforme	suppresses	disease	0.70
neurons	expressed_in	cell_type	0.70
DRP1	inhibits	gene	0.70
OCLN	associated_with	gene	0.70
blood_brain_barrier	maintains	structure	0.70
neurons	promotes	cell_type	0.70
Claudin-5	encodes	protein	0.70
Blood-Brain Barrier	activates	pathway	0.70
DRP1	protects_against	gene	0.70
Stroke	activates	disease	0.65
Als	inhibits	disease	0.65
Ms	therapeutic_target	disease	0.65
Als	therapeutic_target	disease	0.65
Depression	activates	disease	0.65
Carcinoma	inhibits	disease	0.65
Als	expressed_in	disease	0.65
Inflammation	activates	disease	0.65
Vascular Dementia	interacts_with	disease	0.65
STROKE	accumulates_in	disease	0.65
Inflammation	interacts_with	disease	0.65
Dementia	interacts_with	disease	0.65

Incoming (138)

Source	Relation	Type	Str
H6	preserves	hypothesis	0.00
H2_MMP9	cleaves_tight_junction_protein	protease	0.00
miR-181c-5p	represses_translation	miRNA	0.00
ds-f2c28aed24a7	data_in	dataset	1.00
TJP1	interacts_with_confidence_0.993	gene	0.99
OCLN	interacts_with_confidence_0.99	gene	0.99
Autophagy	regulates	process	0.95
Brain Arteriovenous Malformations	downregulates	disease	0.95
BRAIN ARTERIOVENOUS MALFORMATIONS	downregulates	entity	0.95
DTG	downregulates	entity	0.95
Brain Microvascular Endothelial Cells	expressed_in	cell_type	0.92
Drp1 Inhibition	upregulates	mechanism	0.90
ER STRESS	downregulates	entity	0.90
RUPTURED BRAIN ARTERIOVENOUS MALFORMATIONS	downregulates	entity	0.90
CAV1	mediates	protein	0.90
h-7a8d7379	targets	hypothesis	0.90
Cavernomas	associated_with	disease	0.85
DRP1 inhibition	upregulates	drug	0.85
CAV1	regulates	gene	0.85
Autophagy	degrades	process	0.85
Hypoxia	causes	process	0.85
LICOCUMARONE	stabilizes	drug	0.80
CAVERNOMAS	associated_with	entity	0.80
autophagy	degrades	process	0.80
Endoplasmic Reticulum Stress	downregulates	process	0.80
LC3	mediates	entity	0.75
H3K27me3	inhibits	process	0.70
MMP9	cleaves_tight_junction	gene	0.65
AUTOPHAGY	regulates	pathway	0.64
AND	inhibits	gene	0.60
APOE	targets	gene	0.60
INFLAMMATION	activates	gene	0.60
RNA	therapeutic_target	gene	0.60
curcumin	interacts_with	compound	0.60
resveratrol	interacts_with	compound	0.60
ABCB1	activates	gene	0.60
ABCB1	inhibits	gene	0.60
CLDN1	expressed_in	gene	0.60
CDH5	associated_with	gene	0.60
CLDN3	expressed_in	gene	0.60
BLOOD-BRAIN BARRIER DYSFUNCTION	activates	gene	0.60
XBP1	activates	gene	0.60
HSPA5	activates	gene	0.60
ANGPT1	associated_with	gene	0.60
IRE1	activates	gene	0.60
PPP1R15A	activates	gene	0.60
ANGPT1	inhibits	gene	0.60
ACTB	regulates	gene	0.60
TNF	therapeutic_target	gene	0.60
APLP1	interacts_with	gene	0.60

Targeting Hypotheses (5)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Gut-BBB Axis: Tributyrin/Butyrate HDAC Inhibition Epigenetic	0.712	-	Blood-brain barrier permeability changes
Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellu	0.705	-	What blood-brain barrier permeability ch
Vascular and Perivascular Cell Type Vulnerability: BBB Integ	0.566	neurodegeneration	Cell type vulnerability debate in Alzhei
Vascular-Glial Interface Restoration	0.566	neurodegeneration	Cell type vulnerability in Alzheimers Di
HBOT at 1.5 ATA for 90 days restores BBB integrity by upregu	0.460	neurodegeneration	What are the optimal oxygen pressure, du

Mentioning Analyses (7)

Scientific analyses that reference this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (8)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning CLDN5 in their description or question text

No additional research found

CLDN5

Understanding Entity Pages

Summary

Wiki Pages (1)

CLDN5 — Claudin-5

Pathway Diagram

Outgoing (253)

Incoming (138)

Targeting Hypotheses (5)

Mentioning Analyses (7)

What is the minimum effective dose of trazodone required for disease-modifying e

What blood-brain barrier permeability changes serve as early biomarkers for neur

What blood-brain barrier permeability changes serve as early biomarkers for neur

What blood-brain barrier permeability changes serve as early biomarkers for neur

Blood-brain barrier tight junction disruption by neuroinflammatory cytokines

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

Blood-brain barrier transport mechanisms for antibody therapeutics

Experiments (0)

Related Papers (0)

Debates (8)

What is the minimum effective dose of trazodone required for disease-modifying e

What blood-brain barrier permeability changes serve as early biomarkers for neur

What blood-brain barrier permeability changes serve as early biomarkers for neur

What blood-brain barrier permeability changes serve as early biomarkers for neur

Should PEA-PPARA endocannabinoid signaling be prioritized as a therapeutic strat

Blood-brain barrier tight junction disruption by neuroinflammatory cytokines

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc

Related Research